References
- Kitzmiller JP, Barnett CJ, Steiner NS, et al. Buprenorphine: revisiting the efficacy of transdermal delivery system. Ther Deliv. 2015;6:419–422.
- Raffa RB, Ding Z. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain. 2007;9:145–152.
- Kögel B, Christoph T, Straßburger W, et al. Interaction of µ-opioid receptor agonists and antagonists with the analgesic efficacy of buprenorphine in mice. Eur J Pain. 2005;9:599–611.
- Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12(11):1163–1173.
- Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manag. 2011;42(6):903–917.
- Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther. 2007;29(10):2179–2193.
- Munera C, Drehobl M, Sessler NE, et al. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag. 2010;6(3):193–202.
- Breivik J, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand J Pain. 2010;1:122–141.
- Conaghan PG, O’Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthr Cartil. 2011;19:930–938.
- Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–860.
- Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010 May;15(3):169–178.
- James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans® seven-day patches) with buprenorphine sublingual tablets (Temgesic®) in patients with osteoarthritis pain. J Pain Symptom Manag. 2010;40(2):266–278.
- Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 mcg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31(3):503–513.
- CredibleMeds QT-prolonging drugs list; [cited 31 Nov 2016]. Available from: https://crediblemeds.org/
- Kao DP, Haigney MCP, Mehler PS, et al. Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration. Addiction. 2015;110:1468–1475.
- Sessler NE, Walker E, Chickballapur H, et al. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. 2017;129(1):62–68.
- International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: ICH E14. 12 May 2005. [cited 2016 Dec 7]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
- Kapil RP, Cipriano A, Michels GH, et al. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig. 2012;32:583–592.
- Darpo B, Zhou M, Bai SA, et al. Differentiating the effect of an opioid agonist on cardiac repolarization from µ-receptor-mediated, indirect effects on the QT interval: a randomized, 3-way crossover study in healthy subjects. Clin Ther. 2016;38(2):315–326.